Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally admini...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

buymoremakemore Apr. 24 at 3:34 PM

$ALDX Also covered. Seems like theres good support at $1.50

1 · Reply

bernardbaruch Apr. 24 at 1:50 PM

$ALDX I covered thanks gl nia

0 · Reply

flabb Apr. 23 at 8:25 PM

$ALDX out of it at 1.61

0 · Reply

ReversedRunners Apr. 23 at 7:57 PM

$ALDX $CYN $NWBO $MMTLP meta

0 · Reply

JD_Macster Apr. 23 at 6:59 PM

$ALDX No communication whatsoever from management. So disappointing. How could they work a drug for years that was marginally effective? I don’t think there was fraud or even deception at play. I think they were just trying to force it. Not being unbiased in their review of the data. Reproxalap probably works sometimes on some groups or conditions, just not enough to warrant widespread approval and use. Count me as one who believed and took a big hit. Lessons learned for sure.

2 · Reply

Moneymachineuser Apr. 23 at 6:17 PM

$ALDX todd truly f'd all his loyal investors... What a damn shame... Abbvie deal was total peanuts.. there's no recovering from this.. people are minus 6 figures here the LG's it's unreal

0 · Reply

bernardbaruch Apr. 23 at 5:24 PM

$ALDX The technicals are lower highs and lower lows lol

3 · Reply

flabb Apr. 23 at 3:00 PM

$ALDX, it's a pos for sure, but i'll keep it just on the technicals.

0 · Reply

flabb Apr. 23 at 2:59 PM

$ALDX 1.63 bought new player and its a fluke because it's a mistype on my chart, so i saw the chart, and bought it. have no idea what this is going to research now.

1 · Reply

GraceFrey Apr. 22 at 10:46 AM

$ALDX looking golden

2 · Reply

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

Apr 20, 2026, 4:32 PM EDT - 5 days ago

ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 15, 2026, 4:53 PM EDT - 10 days ago

Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their Rights

Apr 7, 2026, 9:02 AM EDT - 18 days ago

Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately

Mar 31, 2026, 10:23 AM EDT - 25 days ago

$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Mar 19, 2026, 9:01 AM EDT - 5 weeks ago

What's Going On With Aldeyra Therapeutics Stock On Thursday?

Mar 17, 2026, 4:33 PM EDT - 5 weeks ago

Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 17, 2026, 8:36 AM EDT - 5 weeks ago

US FDA declines to approve Aldeyra's drug for eye disorder

Mar 17, 2026, 8:30 AM EDT - 5 weeks ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Feb 25, 2026, 10:40 AM EST - 2 months ago

Aldeyra Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 7:01 AM EST - 2 months ago

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Dec 16, 2025, 8:00 AM EST - 4 months ago

Aldeyra Therapeutics Transcript: Study Update

Dec 15, 2025, 7:30 PM EST - 4 months ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Dec 4, 2025, 8:30 AM EST - 5 months ago

Aldeyra Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 6:30 AM EST - 5 months ago

Aldeyra Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 5 months ago

Aldeyra Therapeutics Transcript: R&D Day 2025

Nov 13, 2025, 7:00 AM EST - 5 months ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 5 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 6 months ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Oct 28, 2025, 7:01 AM EDT - 6 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct 10, 2025, 4:32 AM EDT - 7 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALEC BDTX CHRS

Sep 8, 2025, 11:30 AM EDT - 8 months ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:01 AM EDT - 8 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:01 AM EDT - 8 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 8 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 13, 2025, 10:30 AM EDT - 9 months ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:01 AM EDT - 9 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jun 26, 2025, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jun 5, 2025, 4:20 PM EDT - 11 months ago

Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 7:01 AM EDT - 11 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 1 year ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 1 year ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 1 year ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 1 year ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Study Update

May 5, 2025, 6:34 PM EDT - 1 year ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 1 year ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 1 year ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 1 year ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 1 year ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 1 year ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 1 year ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 3, 2025, 5:00 PM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Status Update

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Feb 11, 2025, 9:20 AM EST - 1 year ago

Aldeyra Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Dec 5, 2024, 1:45 PM EST - 1 year ago

Aldeyra Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Nov 21, 2024, 7:30 AM EST - 1 year ago

Aldeyra Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Sep 11, 2024, 11:30 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 8, 2024, 9:00 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Study Update

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Aldeyra Therapeutics Transcript: Status Update

Jun 5, 2024, 3:30 PM EDT - 2 years ago

Aldeyra Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Apr 25, 2024, 9:00 AM EDT - 2 years ago

Aldeyra Therapeutics Transcript: R&D Day 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Aldeyra Therapeutics Transcript: Status Update

Feb 13, 2024, 4:30 PM EST - 2 years ago

Aldeyra Therapeutics Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (virtual)

Dec 19, 2023, 8:00 AM EST - 2 years ago

Aldeyra Therapeutics Transcript: Study Result

Nov 28, 2023, 8:00 AM EST - 2 years ago

Aldeyra Therapeutics Transcript: FDA Announcement

Jun 29, 2023, 8:00 AM EDT - 3 years ago

Aldeyra Therapeutics Transcript: Study Result

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Aldeyra Therapeutics Transcript: Study Result

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Aldeyra Therapeutics Transcript: Study Result

Mar 9, 2023, 8:00 AM EST - 3 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q4 2022

Nov 10, 2022, 11:00 AM EST - 3 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q3 2022

Aug 5, 2022, 8:00 AM EDT - 4 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q2 2022

May 5, 2022, 8:00 AM EDT - 4 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q1 2022

Mar 17, 2022, 8:00 AM EDT - 4 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q4 2021

Oct 28, 2021, 8:00 AM EDT - 4 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q3 2021

Sep 9, 2021, 8:50 AM EDT - 5 years ago

Aldeyra Therapeutics Transcript: Citi’s 16th Annual BioPharma Virtual Conference

Aug 5, 2021, 8:00 AM EDT - 5 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q2 2021

May 6, 2021, 8:00 AM EDT - 5 years ago

Aldeyra Therapeutics Earnings Call Transcript: Q1 2021

Apr 27, 2021, 8:00 AM EDT - 5 years ago

Aldeyra Therapeutics Transcript: Study Result

buymoremakemore Apr. 24 at 3:34 PM

$ALDX Also covered. Seems like theres good support at $1.50

1 · Reply

bernardbaruch Apr. 24 at 1:50 PM

$ALDX I covered thanks gl nia

0 · Reply

flabb Apr. 23 at 8:25 PM

$ALDX out of it at 1.61

0 · Reply

ReversedRunners Apr. 23 at 7:57 PM

$ALDX $CYN $NWBO $MMTLP meta

0 · Reply

JD_Macster Apr. 23 at 6:59 PM

2 · Reply

Moneymachineuser Apr. 23 at 6:17 PM

$ALDX todd truly f'd all his loyal investors... What a damn shame... Abbvie deal was total peanuts.. there's no recovering from this.. people are minus 6 figures here the LG's it's unreal

0 · Reply

bernardbaruch Apr. 23 at 5:24 PM

$ALDX The technicals are lower highs and lower lows lol

3 · Reply

flabb Apr. 23 at 3:00 PM

$ALDX, it's a pos for sure, but i'll keep it just on the technicals.

0 · Reply

flabb Apr. 23 at 2:59 PM

$ALDX 1.63 bought new player and its a fluke because it's a mistype on my chart, so i saw the chart, and bought it. have no idea what this is going to research now.

1 · Reply

GraceFrey Apr. 22 at 10:46 AM

$ALDX looking golden

2 · Reply

bernardbaruch Apr. 21 at 3:09 PM

$ALDX There is no narrative that I am aware of supporting a path to upside from these levels. Not even a squeeze. Annual borrow rate at Fidelity is 0%. Anything this company can pull off will require quite a lot more money than they have on the balance sheet at this time. The whole set up is drawing to an inside straight. At best. Disclosure: short 17,500, no longer trading in this range, looking for a reset lower sooner rather than later based upon tepid tape and lack of legitimate bullish narrative. GL NIA

0 · Reply

Aksunbay Apr. 20 at 5:49 PM

$ALDX What's the deal, Todd? You sold us out and lied to us for years. We got screwed over by the short sellers just so you could live the good life. I hope karma catches up with you.

0 · Reply

bernardbaruch Apr. 20 at 4:29 PM

$ALDX MM’s own this until a real buyer or a real seller shows up. Right now just retail long fatigue and retail short fatigue offsetting each other. Earnings call and Type A meeting next “catalysts” Both pretty predictable imo NIA

0 · Reply

Moneymachineuser Apr. 18 at 1:10 AM

$ALDX Goldman Sachs ?? You thére pal? -$150,000 tell us how it feels

0 · Reply

GoldmanSlaps Apr. 17 at 10:35 PM

$ALDX

0 · Reply

ms1sd Apr. 16 at 5:19 PM

$BCRX i sold 100% of my position today @ +42% gain. It hurt to let go, but unfortunately I held (and still am) $ALDX when I had a similiar gain, only to lose it all and now be down > -50% !!! So I am a whimp. Hoping for a BO for all of you shareholders tho!

2 · Reply

bernardbaruch Apr. 15 at 7:40 PM

$ALDX sold 5000 @1.85 now short 20k I cannot craft a positive scenario for this ticker

4 · Reply

Moneymachineuser Apr. 15 at 6:19 PM

$ALDX where's text with his 500k shares LOL

1 · Reply

Moneymachineuser Apr. 15 at 7:04 AM

$ALDX PO$ stock

0 · Reply

ybk1234 Apr. 13 at 4:20 PM

$ALDX Per Prescription Drug User Fee Act (PDUFA) goals, the target Type A meeting date is within 30 days of receipt of the meeting request. When?

2 · Reply

Moneymachineuser Apr. 13 at 3:14 AM

$ALDX hey I gave everyone the max pain warning, remember my comment I got word from a little birdie about CRL , my cousin she works for a bank as a auditor one of the top seniority, well word is this stock is legit cooked!!!!! You have been warned for the 10th time

1 · Reply

MewKitty Apr. 12 at 4:53 AM

$ALDX FYI - Legal Update: Currently 10 law firms that have transitioned & filed formal court briefs for class actions re ALDX, competing for lead counsel TBD after May 29th: Rosen, Schall, Gross, Bronstein Gewirtz & Grossman (BG&G), DJS, Block & Leviton, Faruqi & Faruqi, Wolf Haldenstein, Robbins Geller, & Pomerantz. Per Chat GPT-5 for ESTIMATES ONLY: Total institutional investors who lost money on March 17, 2026: ≈ 80–130 institutions Total institutional dollar loss (mark‑to‑market or realized that day): ≈ $90–120 million Estimated legal defense costs for ALDX against a single, consolidated class action through resolution (dismissal, settlement, or pre‑trial) = $8–12 million. $70MM - $15M(Milestone-Hercules) -$10M(Legal) = $45M Single Phase 3 DED trial w/ N=500 patients(minimum) typically cost ~$35M You do the math...

0 · Reply

Market Cap	96.29M
Revenue (ttm)	0.00
Net Income (ttm)	-33.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1.93
Profit Margin	0.00%
Debt to Equity Ratio	0.34

Volume	1,481,700
Avg Vol	3,613,012
Day's Range	N/A - N/A
Shares Out	60.18M
Stochastic %K	11%
Beta	1.34
Analysts	Strong Sell
Price Target	$6.40